Access

News

Nature 443, 730-731 (19 October 2006) | doi:10.1038/443730b; Published online 18 October 2006

Open Innovation Challenges

naturejobs

Missing results might have rung warning bell over trial drug

Helen Pearson

Top

Drug-safety experts call for more rigorous risk assessments.

The company whose experimental drug left six volunteers critically ill failed to provide regulatory authorities with relevant data before the trial, claim two experts. They say a checklist could help to ensure more rigorous risk assessment for future applications, especially given the increasing popularity of drugs that act on the immune system.